Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year High - What's Next?

Key Points

• Maze Therapeutics reached a new 52-week high of $28.78, with trading volumes showing increased investor interest.
• Multiple analysts have upgraded their ratings for Maze Therapeutics, with target prices ranging from $34.00 to $50.00, reflecting strong market confidence in the stock's growth.
• Despite reporting a loss of ($0.77) earnings per share, Maze beat analyst estimates, indicating potential for improved financial performance moving forward.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) reached a new 52-week high during trading on Monday . The stock traded as high as $28.78 and last traded at $28.78, with a volume of 12136 shares changing hands. The stock had previously closed at $27.11.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MAZE. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Maze Therapeutics in a report on Thursday, September 18th. Guggenheim lifted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a report on Monday, September 15th. JPMorgan Chase & Co. upped their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an "overweight" rating in a report on Monday, September 29th. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, BTIG Research increased their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Maze Therapeutics presently has an average rating of "Buy" and an average target price of $33.83.

Maze Therapeutics Stock Up 0.2%

The firm has a 50 day simple moving average of $17.98 and a 200 day simple moving average of $13.68.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.

Insider Buying and Selling at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds have recently added to or reduced their stakes in MAZE. New York State Common Retirement Fund purchased a new position in shares of Maze Therapeutics in the 1st quarter worth about $25,000. CWM LLC purchased a new stake in Maze Therapeutics in the second quarter worth approximately $28,000. Corebridge Financial Inc. bought a new position in Maze Therapeutics during the first quarter valued at approximately $48,000. Legal & General Group Plc grew its position in Maze Therapeutics by 387.0% during the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock valued at $52,000 after acquiring an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Maze Therapeutics by 452.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock worth $57,000 after acquiring an additional 3,774 shares in the last quarter.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.